SWOG Cancer Research Network

11/28/2025

S2409 PRISM is a study for people with extensive stage small cell lung cancer (ES-SCLC) who haven’t finished initial treatment. People can also join the study before starting initial treatment.
ES-SCLC can be hard to treat — but this study asks if it’s possible to personalize treatments so people get medicines that work best for them. Patients will get testing to find out which subtype (kind) of extensive stage they have. The study compares the standard treatment, durvalumab, to durvalumab plus a medicine that’s matched to patients’ subtype.
Learn more at SWOG.org/S2409 or call 1-800-4-CANCER and ask about study S2409.

11/22/2025

Many people with muscle invasive have their bladders removed as part of their treatment. But the surgery can have a major impact on quality of life — affecting urinary and sexual health, for example. Clinical trial S2427 (also called BRIGHT) asks if giving people an immunotherapy drug called pembrolizumab (Keytruda) along with radiation therapy can help prevent the need for bladder removal surgery. The study is for people who were treated with chemotherapy, immunotherapy, targeted drugs, or a combination of these — and now the cancer has shrunk or can’t be found.
Learn more at SWOG.org/S2427. Or call 1-800-4-CANCER.

08/25/2025

If you recently finished treatment for — or you will soon — you may be able to join S2417CD.
The trial doesn’t involve any medical treatment. Instead, it’s studying an educational website that was designed for colorectal cancer survivors and their family members or other support people. The site provides information about follow-up care and guidance for talking with a support person about care preferences. Researchers hope to learn if people are more likely to get recommended follow-up care if they’ve used the website.
Learn more at SWOG.org/S2417CD or call 1-800-4-CANCER and ask about study S2417CD.

06/24/2025

Immunotherapy drugs may help a person’s immune system fight cancer. But people can have side effects from them. S2013 is a research study that aims to better predict who is likely to have serious side effects from immunotherapy drugs called immune checkpoint inhibitors.
The study follows patients who are getting treatment that combines these drugs with chemotherapy. People receiving this treatment combination for breast cancer, lung cancer, or gastro-esophageal cancer may be able to join the study.
To learn more, call 1-800-4-CANCER and ask about S2013. Or visit swog.org/S2013.

05/20/2025

The S2408 study is for people planning to have a type of surgery called distal pancreatectomy to treat or a growth on the pancreas. Researchers are aiming to find out if the medicine lanreotide can help prevent pancreatic fistula, a serious surgery complication.
Pancreatic fistula happens when the pancreas has a small leak, and it can cause serious problems — like an infection or uncontrolled bleeding. During the study, researchers will compare lanreotide to a placebo, which contains no medicine.
Learn more at SWOG.org/S2408 or call 1-800-4-CANCER and ask about study S2408.

05/06/2025

Did you finish treatment for early-stage non-small cell lung cancer? If you have no signs of cancer after surgery, you may be able to join S2414.
Right now, doctors don’t know whether people who have no signs of cancer after surgery will benefit from more treatment. But the S2414 study aims to find out if further treatment with an immunotherapy drug called can help keep the cancer from coming back. The study compares treatment with durvalumab to the usual approach — which is when a doctor closely monitors a patient’s health without further treatment.
Learn more at SWOG.org/S2414 or call 1-800-4-CANCER and ask about study S2414.

12/12/2024

New Trial Alert! The PROSPECT-Lung clinical trial is a new NCI study exploring innovative treatment options to help improve outcomes for patients diagnosed with lung cancer. By combining targeted therapies and immunotherapy, the trial seeks to enhance survival rates and quality of life. Find out more here: https://bit.ly/PROSPECTLung

10/23/2024

Testing for certain features in cancer (called biomarkers) can tell doctors about what’s causing the cancer to grow. The study is for adults just diagnosed with acute ( ) or syndrome ( ). It uses advanced biomarker testing to try to match patients with a myeloMATCH clinical trial for cancer treatment. Ask your doctor to learn more. You can also call 1-800-4-CANCER or visit swog.org/myeloMATCH.

07/24/2024

is a large National Cancer Institute (NCI) research study testing treatments for adults with acute myeloid (AML) or syndrome (MDS).
Patients join before starting treatment and may have clinical trial options at all stages of treatment. myeloMATCH uses advanced testing to look for cancer biomarkers that can be targeted by new treatments.
To learn more, visit swog.org/myeloMATCH or call the NCI’s Cancer Information Service at 1-800-4-CANCER.

07/16/2024

S2005 is a for people with ’s (WM). It asks if WM responds better to usual treatment or a new combination of drugs. Learn more at SWOG.org/S2005. Or call 1-800-4-CANCER.

07/05/2024

Study S1937 is for people who had previous treatment for bladder cancer that has spread. It tests adding a newer drug (eribulin) to a usual chemotherapy drug. SWOG.org/S1937. 1-800-4-CANCER.

03/11/2024